Riki Goto
Daiichi Sankyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Riki Goto.
Bioorganic & Medicinal Chemistry Letters | 2017
Takeshi Fukuda; Kenjiro Ueda; Takashi Ishiyama; Riki Goto; Sumie Muramatsu; Masami Hashimoto; Kengo Watanabe; Naoki Tanaka
Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. Inhibition of hepcidin could be a strategy favorable to treating anemia of chronic disease (ACD). We report herein the synthesis and structure-activity relationships (SARs) of a series of indazole compounds as hepcidin production inhibitors. The optimization study of compound 1 led to a potent hepcidin production inhibitor 45, which showed serum hepcidin lowering effects in a mouse IL-6 induced acute inflammatory model.
Bioorganic & Medicinal Chemistry Letters | 2017
Takeshi Fukuda; Riki Goto; Toshihiro Kiho; Kenjiro Ueda; Sumie Muramatsu; Masami Hashimoto; Anri Aki; Kengo Watanabe; Naoki Tanaka
Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. Inhibition of hepcidin could be a strategy favorable to treating anemia of chronic disease (ACD). We report herein the synthesis and structure-activity relationships (SARs) of a series of benzisoxazole compounds as orally active hepcidin production inhibitors. The optimization study of multi kinase inhibitor 1 led to a potent and bioavailable hepcidin production inhibitor 38 (DS79182026), which showed serum hepcidin lowering effects in a mouse IL-6 induced acute inflammatory model.
Bioorganic & Medicinal Chemistry Letters | 2017
Takeshi Fukuda; Riki Goto; Toshihiro Kiho; Kenjiro Ueda; Sumie Muramatsu; Masami Hashimoto; Anri Aki; Kengo Watanabe; Naoki Tanaka
Hepcidin has emerged as the central regulatory molecule in systemic iron homeostasis, and its inhibition could be a favorable strategy for treating anemia of chronic disease (ACD). Here, we report the design, synthesis and structure-activity relationships (SAR) of a series of 4,6-disubstituted indazole compounds as hepcidin production inhibitors. The optimization study of multi-kinase inhibitor 1 led to the design of a potent and bioavailable hepcidin production inhibitor, 32 (DS28120313), which showed serum hepcidin-lowering effects in an interleukin-6-induced acute inflammatory mouse model.
Chemical & Pharmaceutical Bulletin | 2006
Tetsuji Noguchi; Naoki Tanaka; Toyoki Nishimata; Riki Goto; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Fumitoshi Asai; Tomoko Ozeki; Koichi Fujimoto
Chemical & Pharmaceutical Bulletin | 2007
Tetsuji Noguchi; Naoki Tanaka; Toyoki Nishimata; Riki Goto; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Fumitoshi Asai; Koichi Fujimoto
Chemical & Pharmaceutical Bulletin | 2000
Naoki Tanaka; Riki Goto; Rie Ito; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Fumitoshi Asai; Koichi Fujimoto
Chemical & Pharmaceutical Bulletin | 2009
Tetsuji Noguchi; Naoki Tanaka; Toyoki Nishimata; Riki Goto; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Yoichi Niitsu; Fumitoshi Asai; Tomoko Ishizuka; Koichi Fujimoto
Archive | 2010
Takeshi Kuribayashi; Hideki Kubota; Naoki Tanaka; Takeshi Fukuda; Takashi Tsuji; Riki Goto
Chemical & Pharmaceutical Bulletin | 2008
Tetsuji Noguchi; Naoki Tanaka; Toyoki Nishimata; Riki Goto; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Fumitoshi Asai; Koichi Fujimoto
Chemical & Pharmaceutical Bulletin | 1998
Naoki Tanaka; Riki Goto; Rie Ito; Miho Hayakawa; Taketoshi Ogawa; Koichi Fujimoto